Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus

Balletshofer, Bernd; Böckler, Dittmar; Diener, Holger; Heckenkamp, J.; Ito, Wulf; Katoh, Marcus; Lawall, Holger; Malyar, Nasser; Oberländer, Yves; Reimer, Peter; Rittig, Kilian; Zähringer, M.

doi:10.1007/s11428-021-00741-z

Cited by 1 publication

(2 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this regard, risk modifications including abstention from cigarette smoking, blood pressure and lipid-lowering treatments, targeting low density lipoprotein cholesterol (LDL-C) < 55 mg/dL are essential. 20,23 In addition, platelet inhibition is necessary, whereas in patients with poly-vascular disease, the administration of low-dose rivaroxaban needs to be considered. 24 In addition, in patients with diabetes mellitus, the use of glucagon-like peptide-1 (GLP1) analogues and sodium dependent glucose co-transporter 2 (SGLT2) inhibitors is currently recommended to improve cardiovascular outcomes.…”

Section: Discussionmentioning

confidence: 99%

“…19 In addition, in patients with DM, CLTI with ulcers and wound healing disorders can be the first manifestation of PAD, since pain may absent due to diabetic polyneuropathy. 20 In the same context, DM and therewith accompanied conditions, such as polyneuropathy, foot malformation or impaired immune response, may promote the development of ulcerations, maximizing the risk for limb loss in such patients. 21,22 Both in patients with claudication and with CLTI, optimal medical treatment is the cornerstone for the reduction of cardiovascular and limb outcomes.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Safety and Effectiveness of Endovascular Therapy for the Treatment of Peripheral Artery Disease in Patients with and without Diabetes Mellitus

Korosoglou¹,

Giuşcă²,

Langhoff

et al. 2022

Angiology

Self Cite

View full text Add to dashboard Cite

This study investigated the distribution of risk factors, lesion characteristics and endovascular revascularization (EVR) strategies in patients with peripheral arterial disease (PAD) with vs without diabetes mellitus (DM). Data were collected within the RECcording COurses of vasculaR Diseases (RECCORD) registry. Demographic data, lesion localization (iliac vs femoropopliteal vs below-the-knee (BTK)) and lesion complexity score (LCS) based on number of affected segments, and lesion length (< 10 vs 10–20 vs > 20 cm), EVR strategies and peri-procedural complications were analysed in 786 patients with and 1337 without diabetes mellitus. Patients with diabetes mellitus were older (71.6 ± 9.6 vs 69.4 ± 10.5 years, P < .001) and had higher LCS and more often BTK lesions ( P < .05 for all). Lesions were treated less frequently with stents (48.7 vs 59.6%, P < .001) in patients with diabetes mellitus, whereas a non-significant trend was noticed for higher DCB treatment rates (48.3 vs 44.4%, P = .07). Post-interventional ankle-brachial index (ABI) increase was similar (from .77 ± .28 to .92 ± .25 with diabetes mellitus and from .74 ± .21 to .90 ± .20 without diabetes mellitus, P < .001 for both). Peri-/post-procedural complications were low in both groups (4.6%). Patients with diabetes mellitus, who undergo endovascular revascularization are older, have more comorbidities and higher target lesion complexity. However, treatment success rates are similar and complication rates are low.

show abstract

Section: Discussionmentioning

confidence: 99%